Lamivudine data

BCHXF (Laval, Quebec) announced Phase II results from a European and Canadian trial in 51 patients who received one of three oral daily doses in a six-month treatment/six-month follow-up study.

As presented at the meeting of the European Association for the Study of the Liver in Copenhagen, levels of HBV DNA, HB e antigen, and ALT declined during the treatment period, but recovered to varying degrees during the follow up, except in four patents who have remained HBV DNA free. ...